June 28, 2026

Sacred Eye Beauty Launches 30-Day Ritual with GHK-Cu Skin Magic Tablets, FDA 503B GLP-1 Exclusion Comment Deadline Closes Monday June 29, Regulatory Week Ahead: PCAC Testimony Cutoff and Medicare GLP-1 Bridge Launch

Sacred Eye Beauty 30-Day Ritual launches with GHK-Cu/PQQ/Methylene Blue; FDA 503B GLP-1 comment deadline June 29; regulatory week ahead Mon-Wed.

3 stories · Covering industry, regulatory

Editor's Note

Sunday is the lull before three federal regulatory cutoffs land back-to-back. Monday June 29 closes the public comment period (docket 2026-08552, Federal Register May 1) on the FDA's proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list, effectively shutting bulk-compounding of branded GLP-1 substances by FDA-registered outsourcing facilities. Tuesday June 30 closes registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting that will vote on 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon. Wednesday July 1 launches the Medicare GLP-1 Bridge demonstration ($50/month copay through Humana central processing for Foundayo, Wegovy injection and tablets, and Zepbound KwikPen for eligible Part D beneficiaries through December 31, 2027). The compounding-and-coverage frame for the next week's news lands on Monday morning. On the consumer side, Fast Millennial Mode LLC launched Sacred Eye Beauty's 30-Day Ritual on Sunday June 28: a two-step inside-out beauty system pairing the Inside-Out Activator (NAD+, spermidine, vitamin C, MODS Max sublingual delivery) with Skin Magic Tablets (GHK-Cu, PQQ, methylene blue) and positioning copper-tripeptide longevity claims for the mainstream-consumer audience that the 2026 cosmetic peptide wave has been priming all year.

Industry

Sacred Eye Beauty 30-Day Ritual Launches Sunday June 28 with Inside-Out Activator (NAD+, Spermidine, Vitamin C, MODS Max Sublingual Delivery) Paired with Skin Magic Tablets Containing GHK-Cu Copper Peptide, PQQ, and Methylene Blue; Mainstream Consumer Cosmetic Peptide Wave Extends to Inside-Out Longevity Claims

Fast Millennial Mode LLC, founded by entrepreneur Elena Catalina Radu, announced the official launch of Sacred Eye Beauty's flagship 30-Day Ritual on Sunday June 28, 2026. The system has two components. The Inside-Out Activator combines NAD+, spermidine, vitamin C, and MODS Max sublingual-delivery technology in a single daily dose targeting cellular-wellness and healthy-aging markers. The Skin Magic Tablets combine GHK-Cu (copper tripeptide-1), PQQ (pyrroloquinoline quinone), and methylene blue for skin and broader cellular support. The launch fits squarely inside the 2026 mainstream-consumer cosmetic peptide wave that this site has tracked across June: Moes Group's June 6 GHK-Cu private-label manufacturing rollout, CKYN's June 20 GHK-Cu launch, Cosmetics Business's June 2026 feature on eight peptide-anchored beauty launches (Shiseido Ultimune, YSE Beauty Xtreme Glow), and the K-beauty PDRN-peptide-exosome stack. Sacred Eye's differentiator is the inside-out positioning, pairing oral supplementation with topical-equivalent claims. The consumer-channel growth runs in parallel to the regulatory thread: GHK-Cu is one of the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24 agenda for 503A bulks list eligibility.

#sacred-eye-beauty #fast-millennial-mode #ghk-cu #copper-peptide #nad #spermidine #methylene-blue #cosmetic-peptides #consumer-launch #inside-out-beauty

Regulatory

FDA 503B Bulks List GLP-1 Exclusion Comment Deadline Closes Monday June 29 (1 Day Out): Public Comment Window on Proposed Permanent Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Outsourcing Facility Compounding Ends Tomorrow

The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.

#fda #503b #bulks-list #semaglutide #tirzepatide #liraglutide #glp-1-compounding #comment-deadline #outsourcing-facilities

Regulatory

Regulatory Week Ahead (June 29 to July 1): Three Federal Cutoffs in Three Days: 503B GLP-1 Comment Window Closes Monday, PCAC Oral Testimony Registration Closes Tuesday, Medicare GLP-1 Bridge Demonstration Launches Wednesday with Humana Central Processing for $50/Month Eligible Beneficiaries

The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.

#regulatory-calendar #fda #503a #503b #pcac #medicare-glp-1-bridge #humana #balance-model #comment-deadline #compounding-policy